187 related articles for article (PubMed ID: 12523578)
1. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.
Liesveld JL; Abboud CN; Ifthikharuddin JJ; Lancet JE; Wedow LA; Oliva J; Stamm CG; Nichols D
Biol Blood Marrow Transplant; 2002; 8(12):662-5. PubMed ID: 12523578
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
3. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.
Dignani MC; Mykietiuk A; Michelet M; Intile D; Mammana L; Desmery P; Milone G; Pavlovsky S
Bone Marrow Transplant; 2002 Feb; 29(3):263-7. PubMed ID: 11859400
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
Warkentin DI; Epstein JB; Campbell LM; Yip JG; Cox VC; Ransier A; Barnett MJ; Marra F
Ann Pharmacother; 2002 Oct; 36(10):1525-31. PubMed ID: 12243600
[TBL] [Abstract][Full Text] [Related]
5. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.
Orlowski RZ; Mills SR; Hartley EE; Ye X; Piantadosi S; Ambinder RF; Gore SD; Miller CB
Leuk Lymphoma; 2004 Nov; 45(11):2215-9. PubMed ID: 15512809
[TBL] [Abstract][Full Text] [Related]
6. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures.
Miller CS; Cunningham LL; Lindroth JE; Avdiushko SA
J Am Dent Assoc; 2004 Sep; 135(9):1311-8. PubMed ID: 15493396
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
10. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
11. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens.
Gilbert S; McBurney E
Dermatol Surg; 2000 Jan; 26(1):50-4. PubMed ID: 10632686
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
[TBL] [Abstract][Full Text] [Related]
14. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing.
Beeson WH; Rachel JD
Dermatol Surg; 2002 Apr; 28(4):331-6. PubMed ID: 11966791
[TBL] [Abstract][Full Text] [Related]
16. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
Fiddian P; Sabin CA; Griffiths PD
J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
[TBL] [Abstract][Full Text] [Related]
17. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
[TBL] [Abstract][Full Text] [Related]
18. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
